Начало・Списък с акции・Eli Lilly and Co.

Eli Lilly and Co.

Отворен

СекторЗдравеопазване

1,190.47 1.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1154.56

Максимум

1229.94

Ключови измерители
By Trading Economics
Приходи	758M 7.4B
Продажби	507M 20B
P/E Средно за сектора	39.835 68.51
EPS	8.55
Дивидентна доходност	0.54
Марж на печалбата	37.355
Служители	50,000
EBITDA	1.3B 9.7B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+16.79% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	0.54% 2.29%
Следващи печалби	29.10.2026 г.
Следваща дата на дивидент	10.09.2026 г.
Следваща дата на екс-дивидент	14.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	249B 1T
Предишно отваряне	1188.69
Предишно затваряне	1190.47

Настроения в новините

By Acuity

42%

58%

133 / 340 Класиране в Healthcare

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 23:42 ч. UTC

News

Eli Lilly reported second-quarter revenue of $23 billion, raising its full-year guidance to $85 billion to $87 billion. Shares are higher in after-market trading.

4.08.2026 г., 23:02 ч. UTC

Eli Lilly shares are higher in after-market trading, driven by a broader market rally and optimism surrounding potential oil supply agreements.

3.08.2026 г., 20:03 ч. UTC

News

Social Media

Event

Eli Lilly's shares are declining amid negative sentiment despite expanding access to its obesity drug retatrutide and receiving FDA designation for olomorasib.

31.07.2026 г., 23:06 ч. UTC

Eli Lilly and Co shares are higher in after-market trading, though they remain below their 20-day moving average by 2.91%. No specific news was identified.

30.07.2026 г., 21:01 ч. UTC

Eli Lilly shares are higher in after-market trading, recovering from an earlier dip. Broader market sentiment remains positive amid geopolitical tensions and inflation concerns.

29.07.2026 г., 23:26 ч. UTC

Eli Lilly and Co shares are lower in after-market hours amid unusual trading activity. Broader market volatility follows the Federal Reserve's interest rate decision.

28.07.2026 г., 22:06 ч. UTC

Eli Lilly shares are lower in after-market hours, with no specific news identified. Broader market trends may be impacting sentiment following declines in the Nikkei 225 Index.

27.07.2026 г., 23:16 ч. UTC

Eli Lilly and Co shares are lower in after-market hours, continuing a decline since Monday's close amid a broader market downturn. No specific news was identified.

24.07.2026 г., 23:41 ч. UTC

Eli Lilly and Co shares declined in after-market trading, experiencing notable fluctuations without any specific news to explain the price action.

23.07.2026 г., 10:06 ч. UTC

Social Media

Eli Lilly shares are lower in pre-market trading, nearing the $1074–$1003 support zone. Broader market declines coincide with traders awaiting the ECB's interest rate decision.

22.07.2026 г., 23:16 ч. UTC

Social Media

Eli Lilly acquires ATAI for $2.8 billion, entering the psychedelic medicine sector. Shares are higher in after-market trading following the announcement.

21.07.2026 г., 20:07 ч. UTC

Social Media

News

Eli Lilly is higher today, supported by overall market strength and plans to defend against a lawsuit from Novo Nordisk over its weight-loss drugs.

20.07.2026 г., 23:16 ч. UTC

Eli Lilly's shares are roughly flat in after-market trading, amid rising treasury yields and geopolitical tensions affecting interest-sensitive sectors like pharmaceuticals.

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

16.79% нагоре

12-месечна прогноза

Среден 1,366.26 USD 16.79%

Висок 1,600 USD

Нисък 1,135 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

Купи

Задържане

Продай

Според 21 анализатори, дали борсови рейтинги на Eli Lilly and Co. през последните 3 месеца.

Настроение

By Acuity

133 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.